CD8A and neoplasm: When this formulation was tested in mice bearing tumors from B16F10 melanoma cells expressing the p33 antigen, tumor progression was inhibited with a significant increase in total CD8+ T cells and p33-specific T cell infiltration, showing proper anti-tumor protection [24].